Is PepT1 the same as PEPT2?

No. They are related members of the same transporter family with different tissue distributions and different affinities - PepT1 is the high-capacity, lower-affinity intestinal carrier, while PEPT2 is the higher-affinity form found in kidney and elsewhere, including respiratory epithelium. Both are proton-coupled and both carry peptidomimetic drugs.

Does every tripeptide use PepT1?

Most di- and tripeptides are substrates to some degree, because the transporter recognises general features rather than a specific sequence. Affinity varies widely between sequences, and being a substrate is not the same as being a good one.

Does this mean KPV works orally?

It means the published animal studies administered it by mouth and the transporter provides a plausible route by which an intact tripeptide could be absorbed. That is a description of what researchers did in mice, not guidance. Nothing supplied here is for human use by any route.

Why does the transporter matter more than the receptor?

Because the evidence points that way. The transport route has been tested directly with competition, labelled uptake and a genetic knockout. A melanocortin receptor route has not been demonstrated for KPV, and the sequence gives good reason to doubt it.

KPV

The Transporter That Explains the Tripeptide

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

PepT1 is a proton-coupled transporter that carries di- and tripeptides across the intestinal epithelium. Dalmasso and colleagues showed in 2008 that KPV is one of its substrates, and that its reported anti-inflammatory activity in cell models depends on being carried inside by that route.

Key facts

Transporter: PepT1, gene SLC15A1
Substrate range: Di- and tripeptides, and peptidomimetic drugs
Driving force: Transmembrane electrochemical proton gradient
Normal expression: Small intestine; low in healthy colon
In inflammatory bowel disease: Induced in colon
Key paper: Dalmasso G et al., Gastroenterology 2008 (PMID 18061177)
Cells used: Caco2-BBE, HT29-Cl.19A, Jurkat T cells
Reported active range in vitro: Nanomolar

Why a transporter is the interesting part

Most of what is written about KPV starts from what it is a fragment of. That framing puts the emphasis in the wrong place. The single most reproducible finding in the KPV literature is not about melanocortin biology at all - it is that KPV is a substrate for PepT1, the di- and tripeptide transporter, and that its measured effects in cell models depend on that transport happening. Once you know that, the shape of the whole literature makes sense: why the work concentrates on the gut, why the molecule was given by mouth in animal studies when peptides usually cannot be, and why recent papers use KPV as a delivery handle for something else entirely.

What PepT1 actually does

Protein digestion does not end with free amino acids. A substantial share of absorbed nitrogen crosses the intestinal epithelium as intact di- and tripeptides, and PepT1 is the carrier that does it. It is an integral membrane protein of the proton-coupled oligopeptide transporter family, and it moves its substrates uphill against a concentration gradient by coupling transport to the inward movement of protons down the electrochemical gradient maintained at the brush border. Transport is electrogenic: charge moves with the substrate. The relevant consequence is that PepT1 has genuinely broad specificity - it recognises a shape and a charge distribution rather than a particular sequence - which is why it carries thousands of possible di- and tripeptides, and why it also carries peptidomimetic drugs that were never designed with it in mind.

Research material referenced

KPV 10mg — third-party HPLC tested

View — £24.99

Why the colon matters here

PepT1 is normally expressed in the small intestine and is present in the healthy colon only at low levels. Dalmasso and colleagues note that it is induced in the colon during inflammatory bowel disease. That single detail explains why colitis models dominate this literature. A transporter that appears where and when inflammation appears offers something unusual: a route into cells that is upregulated in exactly the tissue and condition of interest. Whether that is a coincidence of biology or something functional is a separate question, and the same 2016 work that tested KPV against it found that the transporter's presence made colitis and its associated tumour burden worse in mice, not better.

What the 2008 experiments actually did

The design is worth setting out because it is stronger than the usual cell-culture study. Human intestinal epithelial lines Caco2-BBE and HT29-Cl.19A and a human T-cell line, Jurkat, were stimulated with pro-inflammatory cytokines with or without KPV, and the response was read out with an NF-kappaB luciferase reporter, Western blot, real-time RT-PCR and ELISA. Separately, transport was measured directly: unlabelled KPV was used as a competitor against a radiolabelled PepT1 substrate, and tritiated KPV was used to determine the kinetics of its own uptake. The reported effects on NF-kappaB and MAP kinase signalling occurred at nanomolar concentrations, and the authors conclude that KPV acts via PepT1 in both immune and epithelial cells.

Why competition plus labelled uptake is the right pair of experiments

Either experiment alone would be weak. Showing that cold KPV competes with a known PepT1 substrate says KPV binds something that substrate also binds - suggestive, but competition can occur without transport. Showing that labelled KPV accumulates in cells says it gets in, but not by which route. Run together, they establish both that KPV interacts with the transporter's binding site and that KPV itself is carried, with measurable kinetics. This is the difference between asserting a mechanism and testing it, and it is why the 2008 paper remains the anchor of this literature nearly two decades later.

What this does not establish

That KPV does anything useful in a person. Everything above is cell lines and mouse models. Nanomolar potency in a luciferase reporter is a statement about a construct in a dish, not about a dose or an exposure in a human being. No clinical trial of KPV has been registered or reported. KPV is supplied here as a material for laboratory research only; it is not a medicine, it is not a treatment for any condition, and nothing in this literature should be read as suggesting otherwise.

Extended research context

The KPV deep dive

Deep dive: two functions in one hormone, and the case for splitting them

Alpha-MSH is a thirteen-residue peptide cleaved from proopiomelanocortin, and it does two things that have almost nothing to do with each other. Its core sequence engages melanocortin receptors on melanocytes and drives melanin synthesis - the activity it is named for. Separately, it carries anti-inflammatory activity that Brzoska and colleagues localised to its C-terminal end, a paper titled 'terminal signal' precisely because the finding was that the signal sits at the terminus rather than in the receptor-binding core. That is an unusually clean functional separation, and it produced two research compounds pulling in opposite directions from one parent. KPV takes the C-terminal three residues and discards the pigmentation activity. Melanotan II does the reverse - a cyclic analogue built around the receptor-binding portion to maximise exactly what KPV was designed to leave behind. Same hormone, opposite halves.

Deep dive: what happens when you shrink a molecule fivefold

Going from alpha-MSH at 1,664.9 Da to KPV at 342.43 Da is not a trim, it is a change of category. A 1,665 Da peptide is firmly a cell-surface ligand - far too large to cross a membrane passively, so whatever it does must begin at a receptor. A 342 Da tripeptide is small enough that intracellular access becomes plausible, which is why KPV's reported mechanism is described in terms of NF-kappaB signalling rather than melanocortin receptor engagement. The consequence is rarely stated: if the fragment acts inside the cell and the parent acts at its surface, then the anti-inflammatory activity of the two is not necessarily the same phenomenon, and read-across between them should run cautiously in both directions. Fragment logic assumes the fragment is the parent minus something. Here it may be the parent minus something plus a different route of access.

Deep dive: the delivery paper is the most informative thing in the literature

Xiao and colleagues published in Molecular Therapy in 2017 on delivering KPV orally using hyaluronic acid-functionalised nanoparticles targeted to inflamed intestinal tissue. Read as a result it is a delivery success. Read as a statement about the compound it is more interesting: nobody builds a targeted nanoparticle carrier for a molecule that already reaches its target. The existence of that work says the free tripeptide's arrival at inflamed tissue was the limiting problem - which follows directly from being 342 Da, highly soluble and rapidly cleared. It is the same signal that CJC-1295's DAC modification carries for growth hormone secretagogues, or that lipidation carries across the whole incretin class: when the engineering effort goes into getting a compound to stay and arrive rather than into making it more active, the pharmacokinetics were the bottleneck.

Research applications

▸Melanocortin fragment structure-activity research
▸NF-kappaB pathway and cytokine production studies in culture
▸Murine models of induced intestinal inflammation
▸Targeted peptide delivery and carrier system development
▸Comparative work on parent hormones and isolated fragments
▸Analytical method development for very short peptides

Handling checklist

✓Verify identity against Lys-Pro-Val, CID 125672, at 342.43 Da
✓Do not search PubChem for 'KPV' - it returns an unrelated organic acid
✓Store lyophilised, cold, dry and dark
✓Use low-binding consumables; a small cationic peptide adsorbs to surfaces
✓Reconstitute gently down the vial wall and swirl, never shake
✓Aliquot into single-use volumes to avoid freeze-thaw cycling
✓Expect no disulfide or oxidation satellites - no cysteine, no methionine

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Searching PubChem for 'KPV' to verify a certificate

Fix: That returns CID 13294447, 2-oxo-5-phenylpentanoic acid at 192.21 Da, an unrelated compound. Search Lys-Pro-Val for CID 125672.

✗ Treating KPV and alpha-MSH findings as interchangeable

Fix: They differ fivefold in mass and the fragment may act intracellularly where the parent cannot. Read across cautiously in both directions.

✗ Assuming a colitis model result speaks to inflammatory bowel disease

Fix: Induced colitis in a mouse is acute and chemical; human IBD is chronic, heterogeneous and immunologically complex.

✗ Expecting to quantify KPV by absorbance at 280 nm

Fix: There is no aromatic residue in the sequence, so there is no usable absorbance there.

✗ Attributing unexplained low recovery to degradation

Fix: KPV is chemically robust - no cysteine, methionine or asparagine. Adsorption to glass and plastic is the more likely cause.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is PepT1 the same as PEPT2?: No. They are related members of the same transporter family with different tissue distributions and different affinities - PepT1 is the high-capacity, lower-affinity intestinal carrier, while PEPT2 is the higher-affinity form found in kidney and elsewhere, including respiratory epithelium. Both are proton-coupled and both carry peptidomimetic drugs.
Does every tripeptide use PepT1?: Most di- and tripeptides are substrates to some degree, because the transporter recognises general features rather than a specific sequence. Affinity varies widely between sequences, and being a substrate is not the same as being a good one.
Does this mean KPV works orally?: It means the published animal studies administered it by mouth and the transporter provides a plausible route by which an intact tripeptide could be absorbed. That is a description of what researchers did in mice, not guidance. Nothing supplied here is for human use by any route.
Why does the transporter matter more than the receptor?: Because the evidence points that way. The transport route has been tested directly with competition, labelled uptake and a genetic knockout. A melanocortin receptor route has not been demonstrated for KPV, and the sequence gives good reason to doubt it.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum